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Mesenchymal stromal cells (MSCs) have enormous intrinsic clinical value due to their
multi-lineage differentiation capacity, support of hemopoiesis, immunoregulation and
growth factors/cytokines secretion. MSCs have thus been the object of extensive research
for decades. After completion of many pre-clinical and clinical trials, MSC-based therapy is
now facing a challenging phase. Several clinical trials have reported moderate, non-durable
benefits, which caused initial enthusiasm to wane, and indicated an urgent need to
optimize the efficacy of therapeutic, platform-enhancing MSC-based treatment. Recent
investigations suggest the presence of multiple in vivo MSC ancestors in a wide range of
tissues, which contribute to the heterogeneity of the starting material for the expansion
of MSCs. This variability in the MSC culture-initiating cell population, together with the
different types of enrichment/isolation and cultivation protocols applied, are hampering
progress in the definition of MSC-based therapies. International regulatory statements
require a precise risk/benefit analysis, ensuring the safety and efficacy of treatments.
GMP validation allows for quality certification, but the prediction of a clinical outcome
after MSC-based therapy is correlated not only to the possible morbidity derived by cell
production process, but also to the biology of the MSCs themselves, which is highly
sensible to unpredictable fluctuation of isolating and culture conditions. Risk exposure
and efficacy of MSC-based therapies should be evaluated by pre-clinical studies, but
the batch-to-batch variability of the final medicinal product could significantly limit the
predictability of these studies. The future success of MSC-based therapies could lie not
only in rational optimization of therapeutic strategies, but also in a stochastic approach
during the assessment of benefit and risk factors.
Keywords: mesenchymal stromal cells, cell-based therapy, clinical applications, cell culture techniques, risk
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INTRODUCTION
In recent years, human mesenchymal stromal cells (MSCs) have
been extensively researched in clinical trials for the treatment
of various bone/articular, immune, neurological, cardiovascu-
lar, gastrointestinal, and blood pathologies (http://clinicaltrials.
gov). The clinical appeal of MSCs is mainly due to their easy
and inexpensive isolation from many different tissues, as well as
their lack of significant immunogenicity (Le Blanc et al., 2003).
The enormous biological value of MSCs is derived by their dif-
ferentiation ability, their immunoregolatory functions and their
production of multiple paracrine growth factors and cytokines
(Bianco et al., 2001; Horwitz et al., 2006; Tyndall et al., 2007;
Shabbir et al., 2009). The MSC clinical value is further increased
by the possibility that all of these various and important func-
tions, could act sinergically administrating a unique cell pop-
ulation. Thus, clinical applications that, for instance, deal with
tissue regeneration basing on the differentiation potential of MSC
(Horwitz et al., 1999; Muguruma et al., 2006), could also take
advantage by their reported support of neo-angiogenesis, to re-
vascularize the new formed tissue (Cao et al., 2005; Au et al.,
2008), as well as immunoregolatory function could modulate
inflammation on the injured site (Glennie et al., 2005; Ringden
et al., 2006). The downside of using MSCs for clinical pur-
poses is that they occur in very low frequency in the tissue of
origin, which forces the use of in vitro expansion protocols in
order to achieve a significant number of cells that are feasible for
transplantation.
MSC-based therapy is currently facing a challenging phase
following the completion of many pre-clinical and clinical tri-
als. Several trials reported moderate, non-durable benefits, which
caused initial enthusiasm to wane, and indicated an urgent
need to optimize the efficacy of therapeutic, platform-enhancing
MSC-based treatment (Allison, 2009; Malliaras et al., 2011;
Tyndall, 2011). The future success of MSC-based therapy lies
in rational optimization of therapeutic strategies, in conjunc-
tion with an adequate assessment of benefit and risk factors
(Liras, 2010).
In this review, emerging concepts on MSC identity, properties
and physiological role (Keating, 2012) are discussed in correla-
tion to important ethical principles and regulatory issues, about
clinical use of these cells. In particular, the evidences of mul-
tiple origins of MSC in the organisms and the characteristic
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heterogeneity of culture expanded MSCs are indicated prevent-
ing a correct risks/benefits evaluation. As a consequence of MSC
multiple origins and heterogeneity, their production results a
high sensible process influenced by a large number of variables
that could be predetermined only in part. In fact, unpredictable
fluctuations in the environmental parameters at the time of sam-
pling and/or during cell manipulation could significantly affect
the final cell product biology. The main critique of this review
discuss the general approach to clinical grade MSC production
that still consider “crude” cell suspension as staring materials (i.e.,
bonemarrowmononuclear cells or stromal vascular fraction) and
uncontrolled culture conditions.
MAJOR PRINCIPLES AND GUIDELINES REGULATING
CLINICAL USE OF MSCs
PRECAUTIONARY PRINCIPLES (PP)
In existing literature, as well as in international treaties and dec-
larations, a variety of PP definitions can be found. It is generally
provided the following widely accepted PP definition: “The pre-
cautionary principle or precautionary approach states that if an
action or policy has a suspected risk of causing harm to the pub-
lic or to the environment, in the absence of scientific consensus that
the action or policy is harmful, the burden of proof that it is not
harmful falls on those taking the action.” In the year 2000, the
European Union (EU) issued a communication regarding the def-
inition of PP: “The precautionary principle applies where scientific
evidence is insufficient, inconclusive or uncertain and preliminary
scientific evaluation indicates that there are reasonable grounds for
concern that the potentially dangerous effects on the environment,
human, animal or plant health may be inconsistent with the high
level of protection chosen by the EU.” Under European Union Law,
application of the precautionary principle has been made a statu-
tory requirement. The EU definition, on the other hand, requires
intervention to maintain the high level of protection chosen by
the EU. Moreover, the EU definition includes two main concepts:
the “uncertainty of scientific evidence” and the “potentially dan-
gerous effects.” These concepts give rise to the general principle
that should be applied in clinical trial design and peer-review, and
which can be summarized as “ensure the safest possible method”
(COM.EST, 2005).
EUROPEAN UNION (EU) REGULATORY ISSUES
In order to applying PP in the definition of new thera-
pies, assuring quality, safety and efficacy the European Union
(EU) proposed a plan of action for the development of new
biotech medicines. This plan included the definition of Advanced
Therapy Medicinal Products (ATMPs) as a new medicinal prod-
uct category that have to fulfill the same scientific and regulatory
standards defined for all the other medicinal product as drugs and
transplants.
A long succession of Directives and Community Regulations,
reviewed in Gálvez et al. (2013), are effective from January the
1st of 2013, and governs the authorization, supervision, release
and pharmacovigilance of AMTPs in EU. AMTPs have been
defined as biological medicinal products containing or consisting
of living cells as well as sub-cellular fractions with biological func-
tions. Thus, AMTPs could not be included in the same category
of drugs and differ from transplants because: (1) They contain
viable human cells of allogeneic or autologous origin undergo-
ing a manufacturing process including substantial manipulations
(as defined in the Regulation (EC) n. 1394/2007, Annex 1); (2)
They may be applied for non-homologous use. Noteworthy, def-
inition of AMTPs is dependent on not only to the production
process but also on their application, considering the concept
of “non-homologous use” which means that cells are admin-
istered in sites where they are not usually present, or to carry
out biological functions that they do not usually take part in
(Figure 1). According to the European regulation, ATMPs include
four different typologies of products: gene therapy medicinal prod-
ucts (GTMP); somatic cell therapy medicinal products (sCTMP);
tissue-engineered products (TEP) and combined advanced therapy
products (CATP) (Schneider et al., 2010). Briefly, GTMP dif-
fer from other AMTPs because they do not include living cells
or tissue, and their medicinal effects are exerted by recombi-
nant nucleic acids. On the contrary, the other AMTPs consist
or contain living cells or tissue in form of cellular preparations
(sCTMP), engineered products (TEP) or in combination with
other medical devices (CATP, Figure 1). These latest products
could be also gathered under the more generic definition of Cell-
based Medicinal Products (CBMPs), where CBMPs are defined as:
“medicinal products presented as having properties for, or used in or
administered to, human beings with a view to treating, preventing
or diagnosing a disease in which the pharmacological, immunologi-
cal or metabolic actions are carried out by cells or tissues” (Figure 1,
pale blue boxed).
As MSCs represent a substantially manipulated cell popula-
tion, due to the culture expansion process, therapeutic products
including these cells, should be classified as ATMPs. More specif-
ically, MSC-based products should be included in the definition
of CBMPs, as MSCs could be possibly applied as cellular suspen-
sion (in sCTMP), as cellular component in engineered bioma-
terials (in TEP) or in combination with other medical devices
like artificial prosthesis, coronary stents, pacemaker leads, etc.
(in CATP).
GOOD MANUFACTURING PRACTICES
In order to prevent any unnecessary and undesired risk exposure
related to cell preparation, storage and transportation proce-
dures, in 1997 the World Health Organization (W.H.O.) defined
Good Manufacturing Practices (GMP) as “that part of qual-
ity assurance which ensures that products are consistently pro-
duced and controlled to the quality standards appropriate to their
intended use and as required by the marketing authorization”
(W.H.O, 1997). GMP covers all aspects of the manufacturing
process. This includes the defined manufacturing process, val-
idated critical manufacturing steps, suitable premises, storage,
transport, qualified and trained production and quality control
personnel, adequate laboratory facilities, approved written pro-
cedures and instructions, records to show all steps of defined
procedures taken, full traceability of a product through batch
processing and distribution records, and systems for recall and
investigation of complaints. The European Union’s GMP (EU-
GMP) guidelines implement similar requirements to those of the
W.H.O. (C.E.C, 1992). The principles described above are general,
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FIGURE 1 | Algorithm for the definition of a Cell-Based Medicinal
Product (CBMP). According to the European Medicines Agency (EMA) a
Biological Medicinal Product should be considered an Advanced Therapy
Medicinal Product (ATMP) if contains, or consist of living cells undergoing
substantial manipulation and/or administered in non-homologous sites.
ATMP includes also medicinal products in which the therapeutic effect is
carried out by organelles or sub-cellular fraction like in Gene Therapy
Medicinal Products (GTMP) that contain or consist of recombinant nucleic
acids. Other ATMPs have been defined as Cell-Based Medicinal Products
(CBMPs, pale blue box) due to the presence of living cells alone as in
Somatic Cell Therapy Medicinal Product (sCTMP), integrated in
bioengineered composites as in Tissue Engineered Products (TEP) or in
combination with other medical devices as in Combined Advanced Therapy
Products (CATP).
and should be applied as governing principles during design,
peer-review and evaluation of the ethical aspects of any clinical
trial.
UNITED STATES (USA) REGULATORY ISSUES
In the USA, MSCs are considered human cells, tissues, or cellular
and tissue-based products (HCT/Ps), as specified in the defini-
tions of The Code of Federal Regulation (CFR) Title 21 §1271 (21
CFR 1271). In 1993, the US FDA began establishing regulatory
and guidance documentation for cell therapies with the issuance
of the Application of Current Statutory Authority to Human
Somatic Cell-therapy and Gene-therapy Products (F.D.A., 1993),
which provided a biologics regulatory framework for the use
of HCT/Ps. The tiered, risk-based approach means that prod-
ucts that present a lower perceived risk will be less regulated,
while products with a larger perceived risk will undergo more
extensive controls and examination. Both will require the cell
products to be manufactured following Good Manufacturing
Practices (GMP), and Good Tissue Practices (GTP). Additional
regulatory requirements will depend on whether the cell
product is “minimally manipulated” or “more-than-minimally
manipulated.”
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According to 21 CFR 1271.10, minimal manipulation criteria
require that:
(1) The HCT/P is minimally manipulated;
(2) The HCT/P is intended for homologous use only, as reflected
by the labeling, advertising, or other indications of the man-
ufacturer’s objective intent;
(3) The manufacture of the HCT/P does not combine the cells or
tissues with another article, except for water, crystalloids, or
a sterilizing, preserving, or storage agent, provided that the
addition of water, crystalloids, or the sterilizing, preserving,
or storage agent does not raise new clinical safety concerns
with respect to the HCT/P; and
(4) Either:
(4.1). The HCT/P does not have a systemic effect and is not
dependent upon the metabolic activity of living cells for its
primary function; or
(4.2) The HCT/P has a systemic effect or is dependent upon
the metabolic activity of living cells for its primary function,
and: (a) is for autologous use; (b) is for allogeneic use in
a first-degree or second-degree blood relative; or (c) is for
reproductive use.
Minimal manipulation means processing that does not alter
the relevant biological characteristics of cells or tissues. HCT/Ps
that do not meet these four major criteria, are considered
more-than-minimally-manipulated HCT/Ps. The FDA has stated
that density-gradient separation, cell selection, centrifugation,
and cryopreservation constitute minimal manipulation. All pro-
cesses that manipulate the cell/tissue product, such as cell
activation, encapsulation, ex vivo expansion, and gene mod-
ifications, are considered more-than-minimal manipulations.
This will mostly be the case in many clinical applications of
MSCs.
RISK FACTOR EVALUATION IN APPLYING MSC EXPANDED
CELLS
The principle of “ensure the safest possible method” should be
applied when evaluating the feasibility of MSC-treatments in
patients. When carrying out clinical trials using MSCs, there
are some existing problems regarding the correct definition of
risks related to the in vitro protocols used to prepare cells. In
fact, the general types of risks reported for a CBMP should
also be reported for MSC preparations. Specifically, human
MSCs are living cells that are usually prepared by extensive cul-
ture in minimal essential media that contains supplements and
reagents of animal origin, such as fetal calf serum and bovine
trypsin. Thus, alongside the infective risk due to cell manip-
ulation, patients treated with these cell preparations also face
prion exposure risk due to the animal origin of the supple-
ments, toxicological risk due to the persistence of toxic agents
such as endotoxin, and immunological risk in case of contam-
inated proteins, peptides or other biomolecules of animal ori-
gin that could persist after cell harvesting and transplantation
(Herberts et al., 2011). GMP procedures are intended to elim-
inate all of these risks and avoid exogenous contamination of
the CBMP, while screening the final product by assaying the
absence of various morbidity agents, such as microbial pathogens
or endotoxins, deterministically assure the safety of the cell prepa-
ration in terms of infective, immunological and toxicological
hazards.
Nonetheless, there are further risks related to the application
of cultured MSCs in clinics, and the fact that risks are exclusively
related to the biology of the cell themselves. In this context, the
application of GMP procedures has no effect on the potential
morbidity of the CBMP. The clinical appeal of MSCs is based on
their high proliferative and differentiative potential, their ability
to secrete cytokines/growth factors and their immunosuppres-
sive function. However, these potentialities could also expose
patients to oncogenic/tumor-supporting risk as well as to the ectopic
differentiation risk (Herberts et al., 2011). There are increasing
evidences that transplantation ofMSCs in humans is safe in terms
of transformation risk. Nonetheless, recent studies reported direct
or indirect MSC-related tumorigenesis, in animals (Lepperdinger
et al., 2008; Momin et al., 2010; Otto and Wright, 2011). A fun-
damental, still debated question is whether expansion of MSCs
could lead to the acquisition of genomic abnormalities and conse-
quently undergo oncogenic transformation. Recent investigations
suggest that an abnormal karyotype not necessarily account for
tumorigenic transformation but could be correlated to cell senes-
cence. (Tarte et al., 2010; Sensebé, 2013; Wang et al., 2013).
However, cell senescence could be related not only to the risk of
transformation but also to the risk of inefficacy and increase in
side effects.
The debated controversies on many aspects of MSC biology
and the application of PP could represent a difficult obstacle
to overcome. In order to facilitate the successful development
of feasible CBMPs, the scientific community has put in great
effort to get more information on the biological mechanism of
MSCs, as well as precise characterization of the cells and repro-
ducible production of the preparation batches. Nonetheless, is
widely accepted that highly heterogeneous and different pop-
ulations can be described under the generic terminology of
MSCs (Ho et al., 2008). The question to be asked, therefore,
is how it can be possible to evaluate risk factors applied to
cells that are still far too ambiguous to be defined. Efficient
prediction of the safety of MSC-based CBMP can be achieved
deterministically for risks concerning exogenous contamina-
tions by applying GMP procedures. On the contrary, precise
evaluation of the intrinsic hazardousness related to the MSC
biology should be done using a stochastic approach. In fact,
sample harvesting, isolation, culture expansion, transport and
administration of MSCs are greatly affected by an intractably
large number of variables. In particular, emerging concepts
such as “multiple ancestors” and “culturing stochastic events”
should be taken into consideration, and attempts should be
made to develop new and more efficient MSC-based therapeutic
strategies.
Moreover, prediction of the beneficial effects of MSC-based
therapy is exclusively correlated to the biology of the expanded
cells, and the heterogeneity of the cell preparations could signif-
icantly affects the proliferative/differentiative potential, and con-
sequently the regenerative potential, as well as immunoregolatory
ability of the CBMP.
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IN VIVO MULTIPLE ANCESTORS OF MSCs AND THE
DETERMINISTIC MODEL
From the very first evidence of the clinical value of the MSC-
based therapies, it was clear that the definition provided by
International Society for Cellular Therapy (ISCT) was not suf-
ficiently stringent to determine a unique and unambiguous cell
population. Different laboratories applied very different isola-
tion protocols, and consequently produced significantly different
cell populations (Wagner and Ho, 2007). These various proto-
cols lead to expanded MSCs that differed greatly in terms of
morphology, phenotype, proliferation and differentiation abil-
ity (Phinney, 2012). Nonetheless, many pre-clinical and clinical
studies were conducted by applying this variety of cell prod-
ucts that were all defined under the widely accepted definition of
MSCs, as a result of the non-stringent criteria of definition. Thus,
themechanism at the basis ofMSC heterogeneity has usually been
correlated not only to biological variability of donors, but also to
a large number of variables, including tissue of origin, cell iso-
lation and obviously, cell culture protocols (Phinney et al., 1999;
Sharma et al., 2014).
While is widely accepted that the successful harvesting of
MSCs, as well as their functionality, is highly affected by sex
(Crisostomo et al., 2007; Deasy et al., 2007), age (Siegel et al.,
2013), disease (Corre et al., 2007; Chen et al., 2012) and the phar-
macological treatment (Lin et al., 2014) of donors, controversies
about influence of tissue origins are still debated (Keating, 2012;
Zhao, 2013). Emerging concepts about the tissue origins of MSCs
suggest that MSCs are virtually present in all organs and tissue
as a consequence of their perivascular localization, and that mild
differences can be detected between expanded MSCs that are iso-
lated from different organs under the same isolating and culture
conditions (da Silva Meirelles et al., 2006). These differences may
have been related to the influence of a modified local environ-
ment (niche) present in a different site of the body. Nonetheless,
MSC isolating protocols usually include different steps in order
to obtain a single cell suspension to be subsequently cultured.
These isolating procedures could significantly differ in relation to
the typology of tissue from which the MSCs should be extracted.
(Pittenger et al., 1999; De Bari et al., 2001; Zuk et al., 2001;
Alessandri et al., 2004; Bi et al., 2007; Barachini et al., 2009).
Recently, a great influence of cell harvesting protocols as enzy-
matic digestion, centrifugation and other enrichment methods
has been hypothesized (Shoshani et al., 2014). Thus, should this
definitely demonstrate that MSCs reside in the vascular network
of virtually all organs with no difference in their biology, as sug-
gested by da Silva et al., the heterogeneity of these cells might be
explained by three possibilities:
(1) There is a unique in vivoMSC ancestor that is affected by the
microenvironment in which it resides,
(2) There is a unique in vivoMSC ancestor that is highly affected
by the isolating procedures,
or
(3) There are multiple in vivo MSC ancestors that vary in pro-
liferation and differentiation ability, which can be isolated in
different portions in relation to the procedure applied.
In the last two decades, collecting evidences account for this third
chance. From the seminal findings that MSCs could be isolated
from the walls of blood vessels (Doherty et al., 1998; Bianco et al.,
2001), strong evidence indicates that the fibroblastoid colonies
originally described by Friedenstein (Friedenstein et al., 1968)
originate from the adventitia of bonemarrow sinusoids (Sacchetti
et al., 2007). Successively, Tormin et al. demonstrated that in vivo
MSC progenitors are not only present in the sub-endothelial layer
of sinusoids but also resides in the trabecular bone-lining cell
population (Tormin et al., 2011). Therefore, there are at least
two cells able to generate MSCs from the bone marrow: one in
the perivascular and one in the endosteal niche. Moreover, our
group recently hypothesized that also lumen-facing layer of bone-
marrow vessels and microvessels could host MSC progenitor,
indicating a possible further MSC ancestors (Pacini and Petrini,
2014).
Similarly, adipose-derived MSCs, have been isolated from
two distinct cell populations represented by pericytes encir-
cling capillaries and microvessels, and adventitial cells sur-
rounding larger arteries and veins (Corselli et al., 2012). MSC-
like cultures can be expanded from both these populations,
suggesting a dual vascular origin for the MSCs of the adi-
pose tissue, similarly to what has been observed in bone
marrow.
The relationship between these different progenitors remains
obscure, despite that they have been largely characterized, and
that many efforts have been made to identify the unique putative
in vivo progenitors of MSCs from the different tissues (Bühring
et al., 2007; Mabuchi et al., 2013).
Most of these studies include the application of immunolog-
ical positive or negative selection of a specific sub-population,
on the basis of a particular marker expression. This significantly
contributes to increased confusion and controversies on the real
identity of the MSC ancestors. In fact, a large number of antibody
panels have been described as feasible for prospective isolation
of MSCs, and various different sub-populations have been cul-
tured to give rise to standard MSC cultures that match the ISCT
criteria (Dominici et al., 2006). Interestingly, many of the identi-
fied ex vivo progenitors that are able to generate a standard MSC
culture are represented by distinct populations. Thus, the search
for the MSC ancestor is turning into a search for various MSC
ancestors.
MSCs are commonly isolated from long-term cultures. It
therefore, remains difficult to determine the primary cells of ori-
gin. The loose ISCT criteria hamper the identification of unique
precursors of MSCs. Indeed, there are several types of primary
cells with different features that can fulfill the definition of MSCs
in vitro. Because the definition is not stringent, the presence of
a unique common precursor for cells with MSC features can-
not be hypothesized. In BM, MSCs can originate from both
perivascular and endosteal progenitors; therefore, it is difficult to
distinguish whether there is a unique common precursor, or if the
loose ISCT definition is unable to identify two different progen-
itor populations. However, the clinical applications of MSCs are
only partially limited by the incomplete characterization of the
progenitor cells.
www.frontiersin.org September 2014 | Volume 2 | Article 50 | 5
Pacini Approaching MSC-based therapies
HETEROGENEITY OF CULTURE EXPANDED MSCs AND THE
STOCHASTIC MODEL
From the beginning of the MSC research, different terms have
described the morphology of these plastic-adherent cells (Werts
et al., 1980; Allen and Dexter, 1983; Kuznetsov et al., 1997; Colter
et al., 2001), together with absence of specific surface markers
to define expanded MSCs, the heterogeneous nature of this cell
population lead to great confusion, made comparison from dif-
ferent studies problematic. Therefore, the differentiation toward
seems to be the more reliable and stringent criteria to define
MSCs. However, variability in the MSC differentiation poten-
tial has been observed between different sources (Strioga et al.,
2012; Hoogduijn et al., 2014), different donors (Phinney et al.,
1999), and also within different colonies obtained from the same
subject (Russell et al., 2010), and also within the same colony
(Digirolamo et al., 1999; Ylöstalo et al., 2008; Sengers et al., 2010).
Thus, the minimum criteria defined early (Horwitz et al., 2005;
Dominici et al., 2006) may now be simplistic and unnecessary
(Keating, 2012).
Therefore, the term “multipotent mesenchymal stromal cells”
does not identify a population of cultured cells with uniform
features and unambiguous potential, but refers to a highly het-
erogeneous population that is dramatically affected by donor
characteristics (Russell et al., 2013), isolation methods (Wagner
and Ho, 2007; Barachini et al., 2009), media supplementation,
seeding density, number of passages and culture time (Muraglia
et al., 2000; Wagner and Ho, 2007; Barachini et al., 2009; Bieback
et al., 2009; Shoshani et al., 2014).
One of the hypotheses about the reason of this variability takes
in account the effects of stochastic events, which possibly occur
during expansion (Pevsner-Fischer et al., 2011).
As discussed above, most of the clinical appeal of MSCs is rep-
resented by the fact that these cells are multipotent progenitors.
This imply that MSCs, in vitro or in vivo, retain the ability to
expand maintaining their features (self-renewal) or to generate
vary cell populations committed toward some specific cell lin-
eages (differentiation) (Mundra et al., 2013). All the actual und
future MSC-based therapies are based on the assumption that
administered MSC are going to meet a specific fate, in which their
could differentiate (i.e., in tissue regeneration) or exert biolog-
ical functions maintaining their biology (i.e., immunregulation
and growth factor production) (Dimarino et al., 2013; Laroni
et al., 2013; Bronckaers et al., 2014). In the recent years, many
efforts have been applied in order to elucidate how primary stem
as well as multipotent progenitor cells “decide” their fate. This
represents a pivotal issue in studying mechanisms leading to tis-
sue development, maintenance and consequently in approaching
new MSC-based therapies (Thirumala et al., 2013).
Pluripotent cells reveal heterogeneous gene expression when
exposed to a constant culture conditions. Recent technical devel-
opments in quantitative single-cell gene expression analysis
(Larson et al., 2009; Raj and van Oudenaarden, 2009) have
produces interesting results suggesting that individual cells can
exhibit transient biases toward different lineages, even in clonal
populations (Hough et al., 2009; Canham et al., 2010; Glotzbach
et al., 2011; MacArthur et al., 2012; Moignard et al., 2013) as a
results of this heterogeneity of gene expression, which might have
a functional role in cell fate decisions. It has also been suggested
that this molecular heterogeneity may result from stochastic fluc-
tuations caused by noisy gene expression (Raser and O’Shea,
2005), leading to fluctuations in individual mRNA transcription
and degradation rates, and in a similar manner for protein pro-
duction, in individual cells (Elowitz et al., 2002; Ozbudak et al.,
2002). These random repression/induction wavering in single-cell
gene expression, predispose pluripotent cells to respond to spe-
cific environmental cues leading to differentiation (MacArthur
and Lemischka, 2013). According to this model, development can
be considered an intrinsically noisy system due to fluctuations
in transcriptional regulation. These fluctuations in gene expres-
sion, that stochastically control cell fate, can be driven by intrinsic
and extrinsic factors. Intrinsic factors result from randomness
inherent to transcription and/or translation, while extrinsic fac-
tors derived from environmental fluctuations (Torres-Padilla and
Chambers, 2014).
Stochastic models explaining gene expression heterogeneity
have been also proposed in vitro for the embryonic stem cells
(ESCs) (Wu and Tzanakakis, 2012), and extended to adult mul-
tipotent progenitor in lineage commitment during hemopoiesis
(Teles et al., 2013). More specifically to MSCs, this model has
been also proposed to account for the plasticity observed in these
cells (Dennis and Charbord, 2002) and recently confirmed in
the cardiomyogenic commitment of bone marrow-derived MSCs
(Yamada et al., 2007).
Thus, not only specific culture conditions could select, or sim-
ply promote, particular subpopulations of MSCs, but in parallel
environmental fluctuations could represent a stochastic prolifera-
tive advantage for individual cells. The hierarchical deterministic
and stochastic model models possibly contribute to explain the
observed morpho-functional variability of MSCs both in vivo,
accounting for their multiple origins, and in vitro generating the
heterogeneity of expanded cells (Figure 2).
DETERMINISTIC AND STOCHASTIC APPROACHES IN THE
EVALUATION OF CBMP FEASIBILITY
Numerous multipotent cell populations has been isolated and
expanded from various tissues, with some of them demon-
strated the ability to differentiate not only toward the mesenchy-
mal lineages but also toward other mesodermal cells (Sarugaser
et al., 2009; Trombi et al., 2009). Moreover, MSC-like cells
have been reported to be able to differentiate also into lin-
eages from the three germ layers: endoderm, mesoderm and
ectoderm (triploblastic differentiation) (Phinney and Prockop,
2007). However, the isolation and successive characterization of
these subpopulations are strictly dependent on the application
of specific culture condition, as well as specific purified culture-
initiating cells (D’Ippolito et al., 2006; Kuroda et al., 2013).
Thus, either mild modifications in the culture determinants
(culture-initiating cells and expansion protocols) or the envi-
ronmental fluctuations during the cell manufacturing processes
could affect the self-renewal/differentiation potential of the final
cell product (Figure 2A), it is reasonable to suppose that a
risks/benefits evaluation of CBMP could be strongly invali-
dated not only by different cell preparation protocols applied,
but also by stochastic events that could take place during this
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FIGURE 2 | Influence of culture determinants and stochastic events on
the biology of bone-marrow-derived MSCs. (A) Recent hypotheses
suggest that MSCs may be derived from different progenitors that vary in
terms of proliferative/differentiative ability and functionality, thus
contributing to a high level of heterogeneity detected among the cell
populations in the final products. Due to the presence of multiple ex vivo
MSC progenitors, (B) different enrichment methods donor variability could
lead to significantly different cell populations in terms of percentage of
these various ancestors (indicated as “Cell Suspension 1” and “Cell
Suspension 2”). Thus, applying different culture protocols (indicated as
“Culture conditions A, B or C”) could select or simply promote specific
subpopulations with different potential. (C) In addiction, even applying
defined protocols, fluctuations in the environmental parameters could
result in unpredictable differences in the culture conditions (indicated as
“Culture conditions C, C1 or C2”) that lastly produce variability in the
efficiency of the cell production process, and in the biology of the final
product (proliferation, differentiation potential, immunoregolatory functions
and growth factors/cytokine production).
phase. Different cell manufacturing processes may lead to signifi-
cantly different cell products to be applied in CBMP preparation
(Figure 2), depending on “macro-differences” in the starting
material (tissue origins, isolating methods) and the cell pro-
duction processes (media and supplements, pale blue arrows in
Figure 2B), and “micro-differences” carried out by unpredictable
parameter fluctuations during sampling (donor-to-donor vari-
ability, donor conditions at the time of sampling, red arrows in
Figure 2B). Moreover, according to stochastic model, environ-
mental parameter fluctuations could give rise to high level of
heterogeneity, even if a defined expansion protocol was applied
(red arrows in Figure 2C).
The possibility to predict the future success of a new
MSC-based therapy is based on the assumption that the cell
population applied in the in vitro and in vivo pre-clinical
studies could be considerate equivalent to that applied in clini-
cal trials. Noteworthy, clinical grade MSC production frequently
forced to alter methods and reagents applied to fulfill GMP
requirements (Fekete et al., 2012). Heterogeneity introduced
by macro-differences could be almost eliminated applying pre-
determined clinical grade conditions also to the production
of the cells designated for pre-clinical testing. Conversely, the
micro-differences could only be phased out with a stochastic
approach, where a particular level of uncertainty could affect a
risk/benefits evaluation. The probability that a produced CBMP
could result in an unexpected effect in treated patients is in
tight correlation with the precise control of as many vari-
ables as possible during the all phases of the cell production
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(Figure 4, red boxes), and the following CBMP manufacture
(Figure 4, black box).
TISSUE ORIGIN
In contrast to reported evidence that tissue origins could only
mildly affect the MSC biology (da Silva Meirelles et al., 2006),
consolidated evidence shows that multipotent MSCs from dif-
ferent sources (i.e., bone marrow, adipose tissue, Worton jelly)
show differences in immunophenotype, proliferation and mul-
tilineage differentiation potential (Ishige et al., 2009; Strioga
et al., 2012). Further investigations are needed to elucidate
whether these modifications are introduced by the niche inter-
actions or by the isolating procedures. In fact, in order to
establish safe procedures for MSC-based CBMP productions,
it is mandatory to set different guidelines for MSCs derived
from any different source, and to standardize nomenclature
that includes the origin of primary cultures, for instance: bone
marrow-derived mesenchymal stromal cells (BM-MSCs) or adi-
pose tissue-derived MSCs (AD-MSCs). Any search for a general
consensus about risk exposure and beneficial effects of general
MSCs that is done independently from the tissue origins risks
failing.
ISOLATING METHODS
Using single cell suspension as starting material is usually
required to initiate an expanding MSC culture protocol. The
methodologies applied to obtain it include tissue digestion, cell
enrichment (i.e., density gradient centrifugation or rosetting) or
even direct isolation of putative in vivo precursors on the basis of
immunophenotypic features (i.e., MSCA-1, CD271, STRO-1 or
SSEA-4) (Gang et al., 2007; Psaltis et al., 2010), adhesion prop-
erties (i.e., MPCs) (Trombi et al., 2009; Fazzi et al., 2011) or
morphological features (i.e., VSEL cells) (Ratajczak et al., 2008).
In order to optimize isolating procedures, it would be useful to
identify the most advantageous methods in terms of quality and
quantity of isolated cells, MSC-colony forming unit frequency
(CFU-MSCs), ease of performing the process, safety in terms
of exposition to exogenous contamination, and costs (Hideki,
2013). Nonetheless, due to the possible multiple origins of
MSCs (Figure 2A) discussed above and the alterations of the cell
composition induced by the ex vivo procedures (Figures 2B,C),
highly purified cell populations are preferable as MCS culture-
initiating cells. A probabilistic prediction of risks and benefits
would be more accurate in reducing biological variability of
starting materials. Highly purified initiating cells would also limit
FIGURE 3 | Deterministic and stochastic approaches in the production of
MSCs. (A) Applying predetermined purified cell populations could drastically
reduce the variability of starting material (indicated as “Purified Cell
Suspension”) enabling the design of defined culture conditions that are specific
to the unique culture-initiating cell population of interest. Nonetheless, applying
uncontrolled culture systems do not prevent from the heterogeneity introduced
by environmental parameter fluctuations, resulting in mild, but significant,
differences in the culture conditions (indicated as “Culture conditions C, C1 or
C2”). (B) Conversely, close culture systems under constant environmental
parameters control, in association with chemically defined media, could
represent feasible tools limiting fluctuations (indicated as “Maintained Culture
Condition C”) and increasing reproducibility of the cell products.
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FIGURE 4 | Ideal MSC-based CBMP production process. Robust
reproducibility in the MSC expansion/production process (red frames) can
be achieved by applying specific isolating methods that are able to supply
defined culture-initiating cells, and highly controlled cell expansion cultures
conducted in computerized close systems. Final product release should be
subjected not only to GMP validation to ensure the bio-safety of the cell
product, but also to quality control validation of the entire production
process. Monitoring and control of environmental parameters can
significantly increase the predictability of the in vitro characterizations and
pre-clinical studies. In fact, drastically reducing the batch-to-batch
heterogeneity of expanded MSCs and consequently of the CBMP produced
(black frame) for different applications (blue frame) could result in less
variation in the clinical outcome, and lastly improve the efficacy of
cell-based therapies.
variability induced by sex, age, diseases and pharmacological
treatments of donors at the time of sampling, that could alter
the composition of simply enriched cell suspensions. However,
environmental fluctuations could still introduce certain level of
heterogeneity of the final product, even if in a lesser extent
(Figure 3A).
CULTURE SYSTEMS
One of the most important factors affecting heterogeneity of cul-
tured MSC is introduced by serum supplementation (Bieback
et al., 2009). Even if it were possible to standardize origins
(bovine or human) or the screening quality of sera, batch-
to-batch variability is related to the unpredictable number of
influencing factors that avoid controlling the concentration of
growth factors, cytokines, hormones and other biomolecules in
the culture media. Similarly, other supplements, such as bovine
pituitary gland or human platelet lysates were affected by the
same uncertainty. In order to accurately predict the feasibility of
MSC-based treatments, any batch-to-batch variability should be
eliminated or drastically reduced. In fact, even if highly purified
cell populations are used as starting materials, it is still possible to
obtain different CBMPs after culturing inmedia that may differ in
some or many biomolecules with potent effects on MSC biology
(Figure 3A).
Chemically defined and xeno-free media (CDM) should be
used in order to more precisely evaluate the clinical value of
expanded MSCs. CDM can be produced under strictly defined
quality control requirements to reduce batch variability and
to guarantee a higher level of reproducibility in the CBMP
production.
Nonetheless, many other culture parameters can affect the
final cell product, such as cell density, time of culture, number
of passages, frequency of media change, temperature fluctuations,
and pH and oxygen tension alterations (D’Ippolito et al., 2006).
In addition, the process of culturing MSCs in open systems,
even if conducted under stringent GMP requirements, may be
affected by the frequent alteration of environmental parameters
such as temperature, PCO2, PO2, pH and humidity that regulates
evaporation/condensation of a medium due to the culture main-
tenance. In fact, the discontinuous medium change includes the
need for moving culture flasks from the incubator to the cab-
inet and vice versa. Processing a large number of flasks and/or
large volumes of medium could result in a significant gap of time
from the first flask processed to the last one, exposing cultures
to unsuitable environmental parameters. Moreover, open systems
require significant manipulation by operators, which exposes the
CBMP production to unpredictable human error. Thus, in the
view of reducing variability in the production process in order
to increase feasibility predictions, employing dedicated bioreac-
tors (i.e., hollow-fibers culture systems) should be mandatory.
In these closed computerized systems, it would be possible to
automate media changes, or even eliminate them, by constant
flow of fresh medium, keeping cultures under proper incubat-
ing conditions and reducing operator involvement. Additionally,
it is important that bioreactors that are employed to produce
clinical grade MSCs are equipped with sensors that monitor cul-
ture parameters such as osmolarity, pH or oxygen tension, and
can produce data-logs of the entire culture process. These appa-
ratuses, especially hollow-fiber culture systems, could also have
two other significant advantages: (1) producing clinical-grade
MSCs in a “closed system,” drastically reducing the risk of exoge-
nous contamination due to the limited culture manipulation, and
(2) provide vast culture surfaces in relative small volumes, mak-
ing cell passaging (sub-cultures) unnecessary. The disadvantage
in applying computerized bioreactors, alongside the significant
increase in cost, lies in the shear stress introduced by the expo-
sition of the cells to a constant liquid flow. Shear stress has been
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reported to significantly affect proliferation and differentiation
potential of MSCs (McCoy and O’Brien, 2010; Yeatts and Fisher,
2011), however this could be easily monitored and controlled in
a computer-assisted culture system, making this parameter also
suitable to intentionally induce particular cell behavior (Yeatts
et al., 2013). Thus, application of CDM in conjunction with envi-
ronmental controlled culture systems could significantly reduce
culture condition fluctuations, increasing reproducibility of the
cell products (Figure 3B).
FINAL PRODUCT RELEASE
Quality control (QC) requirements of the final cell preparations
should be indicated and standardized during the pre-clinical
phase. Alongside microbiological, endotoxin and pyrogenicity
testing, the releasing QCs should include an evaluation of the
number, vitality and senescence of cells, which could affect the
efficacy of the treatment and determination of the minimal dose.
Phenotypes could be also investigated, but the current lack of
specific and widely accepted MSC markers make the immuno-
phenotypization of the CBMP barely determinant in view of
comparative studies. ISCT nomenclature should be refined, and
in addition to standard methods of cell characterization, as sur-
face marker profile and differentiation potential assays, more
advanced molecular tools including assessments of the cell tran-
scriptome, proteome, and secretome should be evaluated in creat-
ing effective and discriminating QC requirements (Keating, 2012;
Ranganath et al., 2012). Moreover, genetic stability of the cell
product should assay, even if a definitive correlation to tumori-
genicity is still lacking. Conventional karyotyping has been sug-
gested to be not sufficient to predict full genome stability, due
to the poor sensitivity and resolution of this test (Barkholt et al.,
2013). Thus, release tests should include genome analysis with
higher performances as comparative genomic hybridization array
(CGH array). Fluorescent in situ hybridization (FISH) analysis
could be also applied to detect recurrent abnormalities that pos-
sibly have been previously associated to long-term culturedMSCs
(Wang et al., 2013).
However, the release of the final product should be primarily
dependent upon the validation of the entire production process.
In fact, the ability to efficiently predict the CBMP response in
humans is correlated to the possibility of assimilating the CBMP
itself to the products evaluated in the pre-clinical tests. Thus,
each phase of the cell preparation should be validated by pre-
determinate requirements, such as the quality of the starting
material (i.e., hemodilution of bone marrow samples), the quality
of the isolating cell population (purity and vitality assay) and the
culture process (data-logs validation).
CELL PRODUCT FREEZING AND STORAGE
Cryopreservation and storage of clinical-grade MSCs offers
unique opportunities to advance the potential uses of these cells,
allowing cell banking, transportation, cell product back-up and
repeated infusions. In clinical banking of MSCs, special consider-
ation should be taken in consideration applying freezing process.
(Thirumala et al., 2013; Sharma et al., 2014). In fact, crypreser-
vation could be assimilated to the culturing expansion process
where crypreservation media, supplements (i.e., animal sera) and
additives (i.e., DMSO) could represent a further cause of expo-
sition to the infective, prion, toxicological and immunological
risks discussed above. Moreover, crypreservation, similarly to cell
expansion, is a process highly sensitive to environmental fluctu-
ations. Thus, consistent and reproducible rates of temperature
change during freezing and thawing are mandatory and could be
only achieved applying automated and controlled devices. In the
same manner the necessary removal of DMSO, as other additive,
should be conducted in close cell washing systems, in order to
maintain GMP compliance. Moreover, constant temperature con-
trol should be assured during long-term storage in pharmaceuti-
cal grade liquid nitrogen (Liras, 2010; Thirumala et al., 2013).
APPLICATION OF MSC-BASED CBMP
Most of the biological features and functions of expanded MSC
can be investigated by applying protocols that may take one to
several weeks to be evaluated. Many of these features are very
important for applying MSC in clinics, and include tumorigene-
ity, tumor support, differentiation potential and immunoregu-
latory functions. Hence, it is not possible to evaluate these very
important biological features at the time of the CBMP release, and
pre-clinical studies are mandatory.
The objectives of the pre-clinical studies are to provide a proof-
of-principle demonstration of the safety and efficacy of a CBMP,
and to define the pharmacological and toxicological effects that
are predictive of the responses in humans. Moreover, there are
several “post-production” factors that are not strictly correlated
to the biology of the CBMP, but that could be influenced by it.
These include administration, supporting pharmacological treat-
ments and follow-up of treated patients. Pre-clinical studies also
allow for the establishment of safe and effective doses, the inves-
tigation of routes and methods of CBMP administration and the
identification of target organs for possible toxicity, which enable
the definition of parameters to be monitored in the patients.
In order to obtain a predictive proof-of-principle demonstra-
tion of a CBMP-based therapy, pre-clinical studies should be
performed in relevant animal models, meaning that the animals
should allow the human response to the CBMP to be predicted.
However, for certain preclinical studies, such as the biodistribu-
tion of cells, a homologous model might provide more valuable
information than xenogeneic models, such as human cells in
immune-suppressed or immunodeficient animals.
CONCLUSIONS
Although MSCs might be considered the most intensely stud-
ied multipotent cell types in cell-based therapy, comparison of
existing pre-clinical and clinical data reveal that the risk/benefit
analysis of an MSC-based treatment may be affected by a
significant level of uncertainty. The reduced predictability of
pre-clinical studies limits the CBMP feasibility required by PP.
Standardization and harmonization of protocols concerning tis-
sue origins, isolating methods, expansion culture, characteri-
zation and quality controls are still lacking. Thus, in recent
years many efforts have been made to establish optimized pro-
tocols for GMP-compliant preparation of MSCs, develop tools
and a catalog of markers for their characterization, and define
their differentiation potential in vitro and in animal models.
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Nonetheless, recent hypotheses suggest that a widely accepted
consensus about MSC preparation could be an out-of-reach goal.
Heterogeneity of MSC ex vivo progenitors, as well as variability
introduced by cell manipulation, do not allow deterministic def-
inition of unique CBMP producing protocol. Culturing MSCs is
not a static procedure, and it is highly sensible to environmen-
tal clues. MSCs are living production factories on their own that
react to environmental clues, in vivo and in vitro, and in response
change their behavior. Using a robust and reproducible produc-
tion regime for these cells is of high necessity, as is the develop-
ment of standardized bioreactors (Figure 4, red boxes). Applying
purified cell populations as culture-initiating cells under specific
and finely controlled culture conditions could strongly increase
the reproducibility of the released CBMPs (Figure 4, black box)
the predictability of the pre-clinical studies regarding for a par-
ticular clinical application, and could result in less variation
in the outcome, as well as boost future clinical applications
(Figure 4, blue box).
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